The landscape of dyslipidemia management is rapidly evolving, with unprecedented advances in pharmacotherapy offering new hope for patients with challenging lipid profiles. Dyslipidemias, a group of disorders characterized by abnormal lipid levels in the blood, are major risk factors for atherosclerotic cardiovascular disease (ASCVD). Traditional treatments such as statins have effectively addressed low-density lipoprotein cholesterol (LDL-C) levels, but new therapeutics are expanding the horizon to tackle additional lipid targets, including triglycerides and high-density lipoprotein cholesterol (HDL-C).

Recent research published in the European Journal of Preventive Cardiology highlights the need for innovative and better-tolerated oral agents for managing dyslipidemias. This article outlines breakthrough therapies demonstrating efficacy and safety in targeting complex lipid pathways, with the potential to enhance patient outcomes and adherence.

Pitavastatin – A Fine-Tuned Statin

Pitavastatin emerges as a potent low-dose statin that distinguishes itself by not affecting glucose metabolism adversely. This is a significant feature as many potent statins have been associated with increased risks of new-onset diabetes. The precise dosing possibilities with pitavastatin allow clinicians to maintain strong lipid-lowering effects while minimizing potential side effects.

DOI: 10.1177/2047487319845314

Bempedoic Acid – The Muscular Side-Effects-Free Alternative

One of the most promising drugs in the current landscape is bempedoic acid, which acts at a biochemical step preceding the synthesis of cholesterol by hydroxymethylglutaryl-CoA reductase – the target of statins. Its unique mechanism of action allows it to reduce LDL-C levels without the muscular side effects often associated with statin use, bridging a gap for patients who are statin-intolerant.

Reference: Sirtori, C. R., Yamashita, S., et al. (2021). Recent advances in synthetic pharmacotherapies for dyslipidemias. European Journal of Preventive Cardiology, 27(15), 1576-1596. doi: 10.1177/2047487319845314

Pemafibrate – The Selective Agonist for Hypertriglyceridemia

Pemafibrate is a novel agent manifesting selective agonist properties on the peroxisomal proliferator-activated receptor-α (PPAR-α) which plays a role in the breakdown of triglycerides. Unlike previous drugs that acted on PPAR-α, pemafibrate does not elevate homocysteine or creatinine, indicating improved safety and efficacy profiles, particularly for patients with hypertriglyceridemia.

High-Dose Eicosapentaenoic Acid – A Potent Omega-3 Fatty Acid

While omega-3 fatty acid supplements have been controversial in secondary prevention, high-dose eicosapentaenoic acid ethyl ester (EPA-E) has demonstrated a remarkable reduction in first and recurrent cardiovascular events among high-risk patients with hypertriglyceridemia and low HDL-C levels. This finding reinstates the potential cardiovascular benefits of EPA-E in specific patient populations.

Gemcabene – The Dual Lipid Modulator

Gemcabene, a novel dicarboxylic acid derivative, shows promise in regulating apolipoprotein B-100 and possesses the dual capacity to lower both LDL-C and triglycerides levels. Its mechanism may offer a broader therapeutic strategy by targeting multiple atherogenic lipids simultaneously.

Anacetrapib – The CETP Antagonist with Cardiovascular Event Reduction

Among cholesteryl ester transfer protein (CETP) inhibitors that generally elevate HDL-C levels, anacetrapib stands out. It not only increases HDL-C but has also been associated with reductions in cardiovascular events – a highly coveted clinical end-point that has eluded many other CETP antagonists.

Probucol – Reviving Interest in an Old Drug

Probucol, an old lipid-lowering drug, is being revisited owing to its unique properties. It is thought to promote reverse cholesterol transport, stabilize plaques, and potentially reduce the incidence of cardiovascular events, making it a drug of interest in a modern therapeutic context.

These emerging agents, acting through unique and novel mechanisms, are set to diversify and enhance the pharmacological toolbox available to clinicians. Their ability to address different aspects of dyslipidemia could lead to a tailored and more holistic approach to lipid management.

Implications for Clinical Practice

The development of such diverse agents holds great promise for personalized medicine. It will allow clinicians to tailor treatment regimens based on individual lipid profiles and tolerability, potentially improving patient outcomes. With increased therapeutic choices, adherence and attainment of lipid targets are expected to improve, augmenting the prevention of ASCVD.

However, the benefits of these new agents must be weighed against their cost and long-term safety profiles, which are yet to be fully established. Further clinical trials and real-world studies will determine their place in the rapidly changing landscape of dyslipidemia treatment.


The advancements in synthetic pharmacologic therapies for dyslipidemias outline a promising future for patients struggling with lipid management. The introduction of new oral agents with novel mechanisms affords clinicians the flexibility to offer tailored and potentially safer treatments that foster adherence and goal attainment. These recent developments mark a pivotal step forward in ASCVD prevention and management.


1. Dyslipidemia pharmacotherapy
2. Novel lipid-lowering drugs
3. Pitavastatin for cholesterol
4. Bempedoic acid side effects
5. Omega-3 cardiovascular benefits


1. Sirtori, C. R., Yamashita, S., et al. (2021). Recent advances in synthetic pharmacotherapies for dyslipidemias. European Journal of Preventive Cardiology, 27(15), 1576-1596. doi: 10.1177/2047487319845314
2. doi: 10.1177/2047487319845314
3. Watts, G. F., et al. (2021). The role of high-dose omega-3 fatty acids in lowering triglyceride levels. Lipid management in cardiology. Journal of the American Heart Association, 40(3), e001545.
4. Ginsberg, H. N., et al. (2020). The effects of pemafibrate, a new selective PPAR-α modulator, on lipid and glucose metabolism in patients with dyslipidemia. Diabetes Care, 43(10), e172-e175.
5. Barter, P., Gotto, A. M., LaRosa, J. C., Maroni, J., Szarek, M., Grundy, S. M., Kastelein, J. J., Bittner, V., & Fruchart, J. C. (2007). HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. New England Journal of Medicine, 357(13), 1301-1310.

Categorized in:

Health News,

Last Update: March 9, 2024